The pharma industry briefing

The latest news, approvals and clinical trials you need to know about this month

Data:
News
in Numbers

$38.5bn

The amount that the global market for blood cancer therapeutics was valued at in 2018 according to BCC Research's report

 21%

The median UK uptake of NICE-approved medicines in the first year after launch compared to comparator countries including the US, France and Germany

 51%

The portion of global industry respondents that believe that drug pricing and reimbursement constraints will have the greatest negative impact on the pharmaceutical industry in 2019

 $14.6bn 

The value of digital health investment in 2018, almost $3 billion more than in 2017 according to a report from Startup Health Insights

236

The reported number of drugs, spanning all stages of development, in the age-related macular degeneration pipeline

Data:
News
in Numbers

$38.5bn  

The amount that the global market for blood cancer therapeutics was valued at in 2018 according to BCC Research's report

51% 

The portion of global industry respondents that believe that drug pricing and reimbursement constraints will have the greatest negative impact on the pharmaceutical industry in 2019

 $14.6bn 

The value of digital health investment in 2018, almost $3 billion more than in 2017 according to a report from Startup Health Insights

21%

The median UK uptake of NICE-approved medicines in the first year after launch compared to comparator countries including the US, France and Germany

236

The reported number of drugs, spanning all stages of development, in the age-related macular degeneration pipeline 

 Growth of cloud computing space offers immense opportunity for pharma in 2019

The total healthcare cloud computing market size is forecast to be almost $35bn in 2022, growing at a Compound Annual Growth Rate (CAGR) of 21.7% between 2018 and 2022 according to GlobalData’s recent report, ‘Cloud Computing in Healthcare – Thematic Research’

Source: GlobalData

 NICE rejects Novartis’ migraine prevention drug Aimovig

Some migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are facing disappointment after NICE rejected it in draft guidance.

The cost-effectiveness watchdog says that it can’t recommend routine NHS use of Aimovig (erenumab) for people suffering at least four migraine episodes each month, even though it is only intended for use after three earlier oral treatments have failed.

Source: Pharmaphorum

 Endometriosis study 'sheds light on links to infertility' say scientists

A new study has cast light on why some women with endometriosis experience infertility, with scientists saying the finding could lead to new treatment options. 

South Korea and US teams say infertility could be linked to deficiency of a protein in womb.

Source: The Guardian

 Researchers redesign a cancer-busting protein without the side effects

For patients with aggressive kidney and skin cancers, an immune-boosting protein called interleukin-2 (IL-2) can be a lifesaver. But the dose at which it fights cancer can also produce life-threatening side effects. 

Now, scientists have used computer modeling to design a new protein from scratch that mimics IL-2’s immune-enhancing abilities, while avoiding its dangerous side effects. The protein has so far been tested only in animals, but it may soon enter human trials.

Source: Science 

 Eli Lilly to buy Loxo Oncology for $8bn

Eli Lilly has announced its intention to buy pioneering cancer treatment development company Loxo Oncology in a deal worth approximately $8bn.


The agreement will cost Lilly $235 per share in cash, in a bid to boost its oncology portfolio with drugs for patients with genomically defined cancers.

Source: Pharma Times

Approvals

 Crizanlizumab (SEG101) 

The US FDA has granted Breakthrough Therapy designation to Novartis’ crizanlizumab for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.

Source: Pharmaphorum

Tyvyt (sintilimab)

Chinese regulator the National Medical Products Administration has approved Innovent's anti-PD-1 antibody Tyvyt for the treatment of patients with classical Hodgkin's lymphoma that has relapsed or refractory after two or more lines of systemic chemotherapy.

Source: The Pharma Letter

Venity (romosozumab)

The Japanese Ministry of Health, Labor and Welfare has granted a marketing authorisation for Amgen’s osteoporosis bone-forming drug for the treatment of osteoporosis in patients at high risk of fracture.

Source: Market Watch

Stivarga (regorafenib)

Bayer’s Stivarga has received a final green light from the National Institute for Health and Care Excellence for use by the NHS to treat advanced liver cancer.

Source: The Pharma Times

Go to top

Share this article